Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Mesoblast Limited ( (AU:MSB) ) just unveiled an update.
Mesoblast has acquired an exclusive worldwide license to a patented chimeric antigen receptor technology platform designed to genetically engineer its mesenchymal stromal cell products for more precise targeting of inflamed tissue. The company obtained the CAR‑MSC intellectual property developed at Mayo Clinic by issuing new ASX ordinary shares to acquire a startup formed to advance the technology, with Mayo providing in‑kind support including GMP manufacturing.
By integrating CAR constructs into its MSC platform, Mesoblast aims to enhance homing, immunomodulation and tissue regeneration, initially targeting ulcerative colitis, Crohn’s disease and B cell‑driven autoimmune conditions such as lupus nephritis. The move is intended to strengthen Mesoblast’s leadership in allogeneic cell therapies, broaden its pipeline into high‑value inflammatory and autoimmune markets, and potentially increase the clinical potency and commercial attractiveness of its existing and future products.
The most recent analyst rating on (AU:MSB) stock is a Buy with a A$3.23 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
More about Mesoblast Limited
Mesoblast Limited is a biotechnology company specializing in allogeneic, off‑the‑shelf cellular medicines for severe and life‑threatening inflammatory conditions. Its therapies are based on proprietary mesenchymal lineage stromal cell platforms, including Ryoncil, the first FDA‑approved mesenchymal stromal cell treatment in the U.S. for pediatric steroid‑refractory acute graft versus host disease.
The company is advancing additional indications for Ryoncil in adult graft versus host disease and biologic‑resistant inflammatory bowel disease, while developing rexlemestrocel‑L for heart failure and chronic low back pain. Mesoblast operates proprietary large‑scale manufacturing, holds an extensive global patent estate running to at least 2044 in major markets, and has commercial partnerships across Japan, Europe and China.
Average Trading Volume: 4,129,653
Technical Sentiment Signal: Sell
Current Market Cap: A$2.74B
Find detailed analytics on MSB stock on TipRanks’ Stock Analysis page.